MARKET

ALEC

ALEC

Alector
NASDAQ
2.360
+0.100
+4.42%
After Hours: 2.360 0 0.00% 16:44 08/21 EDT
OPEN
2.280
PREV CLOSE
2.260
HIGH
2.370
LOW
2.200
VOLUME
728.09K
TURNOVER
--
52 WEEK HIGH
3.400
52 WEEK LOW
1.090
MARKET CAP
262.02M
P/E (TTM)
-2.1614
1D
5D
1M
3M
1Y
5Y
1D
Morgan Stanley Reaffirms Their Sell Rating on Alector (ALEC)
TipRanks · 4d ago
Weekly Report: what happened at ALEC last week (0810-0814)?
Weekly Report · 4d ago
Industry Analysts Just Upgraded Their Alector, Inc. (NASDAQ:ALEC) Revenue Forecasts By 60%
Simply Wall St · 08/12 11:19
Weekly Report: what happened at ALEC last week (0803-0807)?
Weekly Report · 08/10 09:14
Alector (ALEC) Stock Faces Mounting Loss Pressure And Balance Sheet Risk
Simply Wall St · 08/07 23:15
Bank of America Securities Sticks to Its Sell Rating for Alector (ALEC)
TipRanks · 08/07 10:57
Hold Rating Reiterated on Alector as Early-Stage Alzheimer’s Pipeline Keeps Risk–Reward Balanced
TipRanks · 08/07 08:07
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Genmab (GMAB) and Xenon (XENE)
TipRanks · 08/07 08:01
More
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

Webull offers Alector Inc stock information, including NASDAQ: ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.